In a speech to NHS bosses in 2016, Simon Stevens(NHS England’s CEO) urged doctors, nurses and NHS managers to “grab with both hands” the growing opportunitiestechnology offers both to help promote health and tackle the service’s chronic financial problems by saving on treatment and rehabilitation costs.1
Since publication of NICE guidance DG11 in 2013, supporting the use of calprotectin as a cost effective method to differentiate between IBD and IBS, the rates of calprotectin testing in the UK have increased dramatically.
Assays to detect calprotectin have also advanced since then, to assist with changing hospital requirements. These give scalable and flexible solutions that allow hospitals to evolve their calprotectin service in line with increasing demands.
Calprotectin monitoring
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.
